Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03696771 · ClinicalTrials.gov registry record · Phase 1
Study to Determine Safety and Dose of NJH395 in Non-breast HER2+ Advanced Cancer
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT03696771 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 18 participants.
The verdict
NCT03696771, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
A first-in-human study using NJH395 in non-breast HER2-positive advanced malignancies
Interventions
- DRUG NJH395
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2018-12-27 |
| Est. Completion | 2020-10-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03696771
The ClinicalTrials.gov registry entry for NCT03696771 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NJH395 is the first listed.
NCT03696771 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03696771 about?
NCT03696771 is a clinical study titled "Study to Determine Safety and Dose of NJH395 in Non-breast HER2+ Advanced Cancer". A first-in-human study using NJH395 in non-breast HER2-positive advanced malignancies
What is the current status of trial NCT03696771?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2018-12-27. Estimated completion is 2020-10-19.
What interventions are being tested in trial NCT03696771?
The interventions under investigation include: NJH395 (DRUG).
Who is sponsoring clinical trial NCT03696771?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.